Evidence map›Paper›PMID 42266591›Full record

ArticleFrontiers in neurology

Health-related quality of life after direct endovascular thrombectomy and bridging therapy: findings of DIRECT-MT trial.

Renjun Gu, Meihua Huyan, Hongjian Zhang, Fang Shen, Hongjian Shen, Zifu Li, Pengfei Xing, Weilong Hua, Yongxin Zhang, Jianmin Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Renjun Gu *Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Meihua Huyan *Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Hongjian Zhang *Oriental Pan-Vascular Devices Innovation College, University of Shanghai for Science and Technology, Shanghai, China.
Fang ShenNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Hongjian ShenNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Zifu LiNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Pengfei XingNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Weilong HuaNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Yongxin ZhangNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Jianmin LiuNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Pengfei YangNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Lei ZhangNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
Yongwei ZhangNeurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Endovascular thrombectomy (EVT) alone is noninferior to bridging therapy for functional outcomes after large-vessel occlusion stroke in patients directly admitted to comprehensive stroke centers, but effects on health-related quality of life (HRQoL) are uncertain. We compared HRQoL between treatment strategies and assessed effect modification by baseline severity and functional outcomes strata. Methods: This secondary analysis of the DIRECT-MT trial compared EVT alone with bridging therapy. HRQoL at 90 days was measured by EQ-5D-5L index. Quantile regression tested treatment effects on median EQ-5D with interaction terms for baseline NIHSS categories (0-15, 16-20, 21-42) and exploratory 90-day BI and mRS strata. EQ-5D dimensions were analyzed using logistic regression for symptom-free status. Results: Among 656 patients (327 EVT alone; 329 bridging), overall HRQoL among 90-day survivors was similar between groups (median EQ-5D 0.84 vs. 0.85). Baseline stroke severity modified the treatment-EQ-5D association ( Conclusions: HRQoL at 90 days was comparable overall between strategies, but differed by baseline stroke severity. Exploratory analyses suggested additional heterogeneity across achieved functional states and EQ-5D dimensions, supporting further evaluation of baseline severity-guided approaches to optimize patient-centered outcomes.

Indexed as

DIRECT-MT trialendovascular thrombectomyhealth-related quality of lifeintravenous alteplaseischemic stroke

Identifiers

PMID42266591
PMCPMC13243117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.